Showing 581-590 of 1441 results for "".
In That Vein
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/in-that-vein/20646/Sclerotherapy pearls for today's practice.Clinical Updates on Psoriasis Management
https://practicaldermatology.com/topics/psoriasis/clinical-updates-on-psoriasis-management/21496/A Protocol and Literature Review for Indocyanine Green in the Assessment of Periorbital and Facial Lymphatics
https://practicaldermatology.com/youngmd-connect/resident-resource-center/a-protocol-and-literature-review-for-indocyanine-green-in-the-assessment-of-periorbital-and-facial-lymphatics/24016/It’s A Hit! CSF Takes to Music City
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/its-a-hit-csf-takes-to-music-city/23199/If you weren’t at the meeting in Nashville, here’s what you missed.Meet the New Crop of Pigment Correctors
https://practicaldermatology.com/topics/pigmentary-disorders/meet-the-new-crop-of-pigment-correctors/23767/Hydroquinone is no longer the only game in town. In fact, alternatives are now more readily available and show good efficacy.Six Tools to Build Retirement Wealth
https://practicaldermatology.com/topics/practice-management/six-tools-to-build-retirement-wealth/23189/A review of retirement planning tools for doctors and an outline of the rules that govern their use.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Prurigo Nodularis: An Update for Clinicians, Part 2
https://practicaldermatology.com/topics/atopic-dermatitis/prurigo-nodularis-an-update-for-clinicians-part-2/20490/Here's a look at the management of this condition, which is commonly associated with atopic dermatitis.Update on Atopic Dermatitis 2018
https://practicaldermatology.com/topics/general-topics/update-on-atopic-dermatitis-2018/20354/A look at the pathophysiology of AD, including structural and immunologic contributors, as well as new therapeutic developments with an eye toward breakthroughs on the horizon.Lidocaine Shortage: Perspectives, Alternatives, and Pathways Forward
https://practicaldermatology.com/topics/practice-management/lidocaine-shortage-perspectives-alternatives-and-pathways-forward/23949/Supply chain issues, communication barriers, and regulatory inconsistencies cause problems for practitioners and patients.